Aminoverse is a biotech CRO that combines wet lab expertise with artificial intelligence to enhance enzyme research and development, enabling precise enzyme discovery, profiling, and engineering. The company addresses the inefficiencies in traditional enzyme development by providing AI-driven solutions that reduce costs and accelerate the creation of high-performance biocatalysts for various applications.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional enzyme research and development methods, such as random mutagenesis and in silico design, often require numerous iterations, leading to high costs and time investment with limited improvements in enzyme performance. These methods often fail to generate sufficient data, resulting in many projects ending without success.
Solution
Aminoverse is a biotech CRO that enhances enzyme research and development by integrating wet lab expertise with artificial intelligence. The company's AI-driven solutions facilitate precise enzyme discovery, profiling, and engineering, reducing costs and accelerating the creation of high-performance biocatalysts for diverse applications. Aminoverse uses specialized workflows to create holistic enzyme datasets, ensuring accurate AI predictions and reducing risks in enzyme engineering projects. The company offers services such as enzyme discovery using EnzyNAV AI, enzyme profiling with a collection of over 100 assays, and enzyme engineering using proprietary AI technologies like EnzyMAP and EnzyREC.
Target Audience
Aminoverse serves startups, mid-size companies, and large corporations in the pharmaceutical, chemical, and biotechnology industries, as well as academic research institutions seeking to improve enzyme performance, discover new biocatalysts, or optimize enzyme production.
Features
- **EnzyNAV AI:** Utilizes advanced algorithms to filter and identify promising enzyme candidates from datasets of over 2 billion sequences.
- **Enzyme Profiling:** Offers over 100 assays to measure enzyme properties under tunable conditions, with options for custom assay development.
- **EnzyMAP AI:** Predicts the effect of all point mutations across the entire enzyme sequence, reducing screening capacity and budget by 80%.
- **EnzyREC AI:** Predicts the probability of recombinatorial enzyme mutants to fold correctly and be fully functional, combining beneficial mutations into superior enzymes.
- **Holistic Enzyme Libraries:** Customizable libraries with mutations at any desired amino acid position, NGS verified for >95% average correctness, and delivered in a Ready-2-Screen format.
- **Microbial Production Platforms:** Enzyme production in E. coli, B. subtilis, and P. pastoris, with customized up- and downstream processes for yield optimization.
- **UPO Enzyme Panel:** A collection of Unspecific Peroxygenases for the oxyfunctionalization of APIs and intermediates, available from mg to kg scale and free of 3rd party IP.